三阴性乳腺癌细胞系MDA-MB-231与其脑转移细胞系中microRNA差异表达分析

doi:10.3969/j.issn.1004-616x.2021.03.011

Abstract

Abstract: OBJECTIVE： To analyze differentially expressed miRNAs between the triple negative breast cancer cell line MDA-MB-231 (MB-231) and its brain metastasis cell line MDA-MB-231Brm (MB-231Brm)， and to screen biomarkers associated with the brain metastases. METHODS： The Trizol method was used to extract miRNA from MB-231 and MB-231Brm，and PCR was used to construct RNA libraries. After filtering the data and comparing to known miRNA databases，the miRDeep2 method was used to make new miRNA predictions for unknown miRNAs. Then， a differential gene detection method was used to screen the differentially expressed miRNAs. Finally，bioinformatics analysis tools was used to perform functional analysis of the target genes which could be regulated by these miRNAs. Quantitative PCR (qPCR) analyses were used to validate the microarray data. RESULTS： There were differences in the types and expressions of miRNAs between the MB-231 and the MB-231Brm cells. Briefly， 961 kinds of miRNA were shared by both， 164 species of miRNAs only existed in MB-231， and 196 species of miRNAs only existed in MB-231Brm. Compared with MB-231，145 expressions were significantly up-regulated in MB-231Brm，and 64 expressions were significantly down-regulated，and there were no significant differences in 1 122 expressions. Results from differential expression analyses demonstrate that expressions of miR-199a-3p were significantly upregulated in MB-231Brm compared with MB-231 while miR-1246 and miR-4787-5p were down-regulated significantly. GO analyses reveal that genes which were regulated by differentially expressed miRNAs were related to cellular components，molecular functions and biological processes. Results from qPCR analyses confirmed that expressions of miR-1246 were down- regulated in MB-231Brm， compared with MB-231 (P < 0.05). CONCLUSION： There were differentially expressed miRNAs in MB-231 and MB-231Brm cells， and genes that were targeted by these miRNAs were associated with cellular components， molecular functions and biological processes during TNBC brain metastasis. Moreover， expressions of miR-1246 were down-regulated in MB-231Brm，compared with MB-231. Therefore， miR-1246 may participate in the occurrence and development of TNBC brain metastasis.

Key words: triple negative breast cancer, brain metastasis, differentially expression, microRNA, miR-1246

CLC Number:

R737.9

LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.

References

[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] BIANCHINI G, BALKO J M, MAYER I A, et al. Triplenegative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690.
[3] LEE A, DJAMGOZ M B A. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies[J]. Cancer Treat Rev, 2018, 62: 110-122.
[4] BAUER K R, BROWN M, CRESS R D, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California Cancer Registry[J]. Cancer, 2007, 109(9): 1721-1728.
[5] KWAN M L, KUSHI L H, WELTZIEN E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors[J]. Breast Cancer Res, 2009, 11(3): R31.
[6] LIN N U, CLAUS E, SOHL J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triplenegative breast cancer: high incidence of central nervous system metastases[J]. Cancer, 2008, 113(10): 2638-2645.
[7] DAWOOD S, LEI X D, LITTON J K, et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer[J]. Cancer, 2012, 118(19): 4652-4659.
[8] MARTIN A M, CAGNEY D N, CATALANO P J, et al. Brain metastases in newly diagnosed breast cancer: a populationbased study[J]. JAMA Oncol, 2017, 3(8): 1069-1077.
[9] ACHROL A S, RENNERT R C, ANDERS C, et al. Brain metastases[J]. Nat Rev Dis Primers, 2019, 5(1): 1-26.
[10] TSENG L M, HSU N C, CHEN S C, et al. Distant metastasis in triple-negative breast cancer[J]. Neoplasma, 2013, 60(3): 290-294.
[11] MORIKAWA A, WANG R, PATIL S, et al. Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2-targeted therapy: an argument for earlier detection[J]. Clin Breast Cancer, 2018, 18(5): 353-361.
[12] SALVATI M, TROPEANO M P, MAIOLA V, et al. Multiple brain metastases: a surgical series and neurosurgical perspective [J]. Neurol Sci, 2018, 39(4): 671-677.
[13] BOWMAN K M, KUMTHEKAR P. Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma[J]. Future Oncol, 2018, 14(4): 391-407.
[14] PIASECKA D, BRAUN M, KORDEK R, et al. MicroRNAs in regulation of triple-negative breast cancer progression[J]. J Cancer Res Clin Oncol, 2018, 144(8): 1401-1411.
[15] KONG P, CHEN L, YU M X, et al. miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triplenegative breast cancer[J]. Cell Death Dis, 2018, 9(11): 1059.
[16] CHU J H, LI Y F, FAN X M, et al. MiR-4319 suppress the malignancy of triple-negative breast cancer by regulating selfrenewal and tumorigenesis of stem cells[J]. Cell Physiol Biochem, 2018, 48(2): 593-604.
[17] HONG Z P, HONG C Y, MA B, et al. MicroRNA-126-3p inhibits the proliferation, migration, invasion, and angiogenesis of triple-negative breast cancer cells by targeting RGS3[J]. Oncol Rep, 2019, 42(4): 1569-1579.
[18] LEGENDRE M, AUDIC S, POIROT O, et al. mRNA deep sequencing reveals 75 new genes and a complex transcriptional landscape in Mimivirus[J]. Genome Res, 2010, 20(5): 664-674.
[19] VAN'T VEER L J, DAI H Y, VAN DE VIJVER M J, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871): 530-536.
[20] MA X J, DAHIYA S, RICHARDSON E, et al. Gene expression profiling of the tumor microenvironment during breast cancer progression[J]. Breast Cancer Res, 2009, 11(1): R7.
[21] REIS-FILHO J S, PUSZTAI L. Gene expression profiling in breast cancer: classification, prognostication, and prediction[J]. Lancet, 2011, 378(9805): 1812-1823.
[22] ZOHRABIAN V M, NANDU H, GULATI N, et al. Gene expression profiling of metastatic brain cancer[J]. Oncol Rep, 2007, 18(2): 321-328.
[23] ZHOU L, GAO H F, LIU D S, et al. Gene expression profiling of brain metastatic cell from triple negative breast cancer: Understanding the molecular events[J]. Gene, 2018, 640: 21-27.
[24] ZHANG Y, LIAO J M, ZENG S X, et al. p53 downregulates Down syndrome-associated DYRK1A through miR-1246[J]. EMBO Rep, 2011, 12(8): 811-817.
[25] LIAO J M, ZHOU X, ZHANG Y, et al. MiR-1246: a new link of the p53 family with cancer and Down syndrome[J]. Cell Cycle, 2012, 11(14): 2624-2630.
[26] MALLA R R, KUMARI S, GAVARA M M, et al. A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer[J]. Biophys Rev, 2019, 11(2): 227-234.
[27] TAKESHITA N, HOSHINO I, MORI M, et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma[J]. Br J Cancer, 2013, 108(3): 644-652.
[28] SUN Z, MENG C T, WANG S H, et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 616.
[29] HUANG W H, LI H F, LUO R C. The microRNA-1246 promotes metastasis in non-small cell lung cancer by targeting cytoplasmic polyadenylation element-binding protein 4[J]. Diagn Pathol, 2015, 10: 127.
[30] YUAN D X, XU J P, WANG J, et al. Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5[J]. Oncotarget, 2016, 7(22): 32707-32722.
[31] LIN S S, PENG C Y, LIAO Y W, et al. miR-1246 targets CCNG2 to enhance cancer stemness and chemoresistance in oral carcinomas[J]. Cancers (Basel), 2018, 10(8): E272.
[32] TODESCHINI P, SALVIATO E, PARACCHINI L, et al. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts[J]. Cancer Lett, 2017, 388: 320-327.
[33] HANNAFON B N, TRIGOSO Y D, CALLOWAY C L, et al. Plasma exosome microRNAs are indicative of breast cancer[J]. Breast Cancer Res, 2016, 18(1): 90.
[34] LI X J, REN Z J, TANG J H, et al. Exosomal microRNA MiR-1246 promotes cell proliferation, invasion and drug resistance by targeting CCNG2 in breast cancer[J]. Cell Physiol Biochem, 2017, 44(5): 1741-1748.
[35] LIAO J M, ZHOU X, ZHANG Y, et al. MiR-1246: a new link of the p53 family with cancer and Down syndrome[J]. Cell Cycle, 2012, 11(14): 2624-2630.
[36] ZHANG Q, CAO L Y, CHENG S J, et al. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB[J]. Oncol Rep, 2015, 33(3): 1335-1341.
[37] SHAH S P, ROTH A, GOYA R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers[J]. Nature, 2012, 486(7403): 395-399.
[38] WALERYCH D, NAPOLI M, COLLAVIN L, et al. The rebel angel: mutant p53 as the driving oncogene in breast cancer[J]. Carcinogenesis, 2012, 33(11): 2007-2017.
[39] TURNER N, MORETTI E, SICLARI O, et al. Targeting triple negative breast cancer: is p53 the answer?[J]. Cancer Treat Rev, 2013, 39(5): 541-550.
[40] LIU R Z, VO T M, JAIN S, et al. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer[J]. J Pathol, 2019, 247(2): 186-198.
[41] CUSTÓDIO-SANTOS T, VIDEIRA M, BRITO M A. Brain metastasization of breast cancer[J]. Biochim Biophys Acta Rev Cancer, 2017, 1868(1): 132-147.

Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	LIU Peng, BAI Yixiao. Effect of miR-29a on proliferation and migration of human gastric cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 452-456,463.
[2]	CAI Ying, LI Runbing, ZHENG Kai, QIN Shuangjian, LI Boru, ZHANG Zhaohui, XU Xinyun. Differential microRNAs expression and bioinformatics analyses in HBE cells exposed to PM_2.5 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 355-362.
[3]	Lü Yanping, WU Chuancheng, YANG Shuangfeng, HE Chenzhou, HAN Renjie, YAN Wei, LIU Baoying. Relationship between differentially expressed miRNA-SNPs and prognosis of gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 380-386.
[4]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[5]	MA Lili, ZHANG Shuli, LI Qin, XU Peng, FENG Min, LI Xiumei. Screening and identification of differentially expressed miRNAs in esophageal cancers among Xinjiang Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 52-56.
[6]	WEN Zhuan, TAN Bibo, LI Yong, ZHAO Qun, FAN Liqiao, WANG Dong, ER Limian. Expression of miR-95 and susceptibility to lobaplatin in gastric cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 363-367,372.
[7]	CUI Bao-di，WU Yang#，SUN Zhen-xiao*. Protective effect of norcantharidin on ischemia-reperfusion injury in rat cardiomyocytes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(6): 423-427.
[8]	UAN Wei-xin，JIANG Yan-ping，XIE Chun-jiao，QIN Fei，CHEN Yun-cong，WEI Qing，ZENG Xiao-wen，SHA Yan，XIAO Yong-mei，*. The regulatory role of miR-146a in the differentiation of HL-60 cells inhibited by hydroquinone [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(3): 165-170.
[9]	ZHANG Yan-qiu，WANG Xi-kai，ZHANG Juan，YIN Li-hong，PU Yue-pu，LIANG Ge-yu*. Effect of high-dose benzo (a)-pyrene on microRNAs expression in mice lung tissues [J]. , 2012, 24(2): 86-90.
[10]	LIU Hui1, LIU Ran1, SU Yao-yao1,YANG Miao1,PU Yue-pu1,YIN Li-hong1,,WANG Yi2,PAN En-chun2,GUO Wei3,YOU Zhen-bin3. A pilot study of differentially expressed microRNAs between esophageal squamous cell carcinoma and adjacent tissues in Huai'an population [J]. , 2010, 22(6): 418-422.